COVID-19: Keep up to date with the latest pharmaceutical and healthcare news as the pandemic evolves

Keeping pace

Environmental risk, biosafety and other key regulatory considerations for cell and gene therapy trials
(New) terms of engagement

With the pandemic and structural reforms taking their toll on the NHS workforce, Oli Hudson looks at how pharma can develop a sensitive and intelligent engagement approach that reflects the climate of change and uncertainty faced by clinical teams
Doctors in chains?

The reality of prescribing freedoms in the UK

News

View all

Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients

Immunotherapy combo approved for the treatment of advanced bowel cancer patients with rare MSI-H/dMMR mutations

14th June 2021

Vertex, CRISPR Therapeutics’ blood disorder gene therapy shows more promise

CTX001 is being evaluated as a one-time treatment for transfusion dependent beta thalassemia and sickle cell disease

14th June 2021

NICE to reassess Kyowa Kirin’s Poteligeo

An appeal lodged by the company and various charities has been upheld by an independent appeal panel

14th June 2021

UK to donate 100 million surplus COVID-19 vaccine doses

Gov’t will donate five million of the surplus doses by the end of September

14th June 2021

New hybrid healthcare agency Stirred launches

Stirred has been launched this week by former senior Pegasus colleagues Jo Spadaccino and Stuart Hehir

11th June 2021

Web Exclusives

View all

How a data fabric can accelerate clinical trials

Clinical trials must deal with extreme amounts of diverse data which are generated across several institutions. A flexible data architecture can help shorten the journey to approval and distribution

Safety first

Professor Saad Shakir on the gap in public knowledge about routine drug safety and pharmacovigilance activity

Knowledge beyond borders

Delivering internal and external diversity in pharma

Smart People: Jeff Elton

Jeff Elton, chief executive of ConcertAI, talks to PharmaTimes about the pandemic's impact on oncology trials in the US

Magazine

View more from the latest edition

Young Leaders: Lydia Oikonomidis

Lydia Oikonomidis, Langland, Scientific Strategist

Young Leaders: Nicole Corteen

Nicole Corteen, Langland, Principal Medical Writer

Young Leaders: James Addicott

James Addicott, Four Health, Senior Account Director

Young Leaders: Rebecca Godfrey

Rebecca Godfrey, Four Health, Account Director

Young Leaders: Lucy Goodwill

Lucy Goodwill, Four Health, Account Manager

Young Leaders: Robyn Wagner

Robyn Wagner, Havas Lynx, Group Account Director

The Best of Business Intelligence 2021

Winners of the 2021 Best of Business Intelligence (BOBI) awards

The shape of it

Should pharma companies consider protecting the shape of their products?

MAGAZINE EXCLUSIVE

Thought Leadership

View all

Defining optimal patient pathways in a fast-changing NHS

Steve How explains how Wilmington Healthcare's unique behavioural methodology is being used to map patient journeys across the integrated care landscape

Why virtual engagement will be key to pharma strategy in 2021 and beyond

Life science companies were challenged by the sudden shift in ways of working as the COVID-19 pandemic began. But in moving critical work and even some large-scale events to virtual platforms, pharmaceutical teams learned valuable lessons and embraced new technologies that will become part of their long-term strategy.

What does the future of cancer care in the UK look like?

The COVID-19 pandemic has brought into question how we approach care across multiple disease areas in the future. But what does this mean in cancer? Hear from Bristol Myers Squibb’s (BMS) Executive Medical Director, Hubert Bland, who believes that in order to advance in cancer care, we must learn from the COVID-19 response and adopt a collaborative approach across the healthcare industry.